Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.12M | 2.74M | 2.32M | 2.81M | 2.72M |
| Gross Profit | -2.12M | -2.74M | -2.32M | -2.81M | -2.72M |
| SG&A Expenses | 2.56M | 2.61M | 2.15M | 1.98M | 2.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.68M | 5.35M | 4.47M | 4.79M | 5.09M |
| Operating Income | -4.68M | -5.35M | -4.47M | -4.79M | -5.09M |
| Income Before Tax | -4.57M | -5.43M | -4.47M | -4.74M | -5.67M |
| Income Tax Expenses | 104.10K | 183.10K | 70.10K | 549.30K | 141.20K |
| Earnings from Continuing Operations | -4.68M | -5.61M | -4.54M | -5.28M | -5.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.68M | -5.61M | -4.54M | -5.28M | -5.81M |
| EBIT | -4.68M | -5.35M | -4.47M | -4.79M | -5.09M |
| EBITDA | -4.67M | -5.34M | -4.46M | -4.78M | -5.09M |
| EPS Basic | -0.11 | -0.13 | -0.12 | -0.15 | -0.19 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.07 | -0.08 | -0.12 |
| EPS Diluted | -0.11 | -0.13 | -0.12 | -0.15 | -0.19 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.07 | -0.08 | -0.12 |
| Average Basic Shares Outstanding | 42.88M | 42.23M | 37.82M | 35.00M | 30.34M |
| Average Diluted Shares Outstanding | 42.88M | 42.23M | 37.82M | 35.00M | 30.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |